CN110621675B - 用于治疗增殖性疾病的三环化合物 - Google Patents

用于治疗增殖性疾病的三环化合物 Download PDF

Info

Publication number
CN110621675B
CN110621675B CN201880031972.3A CN201880031972A CN110621675B CN 110621675 B CN110621675 B CN 110621675B CN 201880031972 A CN201880031972 A CN 201880031972A CN 110621675 B CN110621675 B CN 110621675B
Authority
CN
China
Prior art keywords
hydroxy
alkyl
indol
propyl
pyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880031972.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN110621675A (zh
Inventor
安德鲁·莫利
丽贝卡·米勒
尼古拉斯·拉·唐格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aguno Treatment Co ltd
Original Assignee
Aguno Treatment Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aguno Treatment Co ltd filed Critical Aguno Treatment Co ltd
Publication of CN110621675A publication Critical patent/CN110621675A/zh
Application granted granted Critical
Publication of CN110621675B publication Critical patent/CN110621675B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN201880031972.3A 2017-03-17 2018-03-16 用于治疗增殖性疾病的三环化合物 Active CN110621675B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1704325.8A GB201704325D0 (en) 2017-03-17 2017-03-17 Compounds
GB1704325.8 2017-03-17
PCT/EP2018/056675 WO2018167276A1 (en) 2017-03-17 2018-03-16 Tricyclic compounds for use in treatment of proliferative disorders

Publications (2)

Publication Number Publication Date
CN110621675A CN110621675A (zh) 2019-12-27
CN110621675B true CN110621675B (zh) 2023-09-19

Family

ID=58688220

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880031972.3A Active CN110621675B (zh) 2017-03-17 2018-03-16 用于治疗增殖性疾病的三环化合物

Country Status (9)

Country Link
US (1) US11274098B2 (https=)
EP (1) EP3596073B1 (https=)
JP (1) JP7308765B2 (https=)
KR (1) KR102604942B1 (https=)
CN (1) CN110621675B (https=)
CA (1) CA3056726A1 (https=)
ES (1) ES2925115T3 (https=)
GB (1) GB201704325D0 (https=)
WO (1) WO2018167276A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201905780D0 (en) 2019-04-25 2019-06-05 La Thangue Nicholas Cancer therapy
KR102278691B1 (ko) * 2019-08-09 2021-07-16 한국화학연구원 신규한 피리미딘 설폰아마이드 유도체
KR102282712B1 (ko) * 2019-08-09 2021-07-27 한국화학연구원 신규한 피리미딘 설폰아마이드 유도체를 유효성분으로 포함하는 암 예방 또는 치료용 약학 조성물
WO2021029450A1 (ko) * 2019-08-09 2021-02-18 한국화학연구원 신규한 피리미딘 설폰아마이드 유도체 및 이를 유효성분으로 포함하는 암 예방 또는 치료용 약학 조성물
JP7609857B2 (ja) 2019-10-02 2025-01-07 エスケー バイオファーマスティカルズ カンパニー リミテッド 二環式化合物及びその使用
CN111454260B (zh) * 2020-05-25 2023-02-28 贵州大学 一类含异丙醇胺亚结构的1，2，3，4-四氢-β-咔啉类化合物及其制备方法和应用
CN111892593B (zh) * 2020-08-19 2021-11-16 南通大学 一种8-甲氧基-5H-吡啶并[4,3-b]吲哚及其合成方法
JP2024508235A (ja) * 2021-02-04 2024-02-26 アムジエン・インコーポレーテツド 三環－アミド－二環ｐｒｍｔ５阻害剤
CN113105517B (zh) * 2021-04-10 2022-03-01 台州仙琚药业有限公司 雄甾-1,4,9-三烯-3,17-二酮的合成方法
GB202108383D0 (en) * 2021-06-11 2021-07-28 Argonaut Therapeutics Ltd Compounds useful in the treatment or prevention of a prmt5-mediated disorder
GB202117230D0 (en) 2021-11-29 2022-01-12 Argonaut Therapeutics Ltd Peptide vaccine
GB202203588D0 (en) 2022-03-15 2022-04-27 Argonaut Therapeutics Ltd Cancer diagnostic
CN115521306B (zh) * 2022-09-26 2024-03-26 贵州大学 一种1,2,3,4-四氢-β-咔啉衍生物及其制备方法和应用
CN117088891A (zh) * 2023-07-13 2023-11-21 浙江大学 含四氢苯并[4,5]呋喃[2,3-c]吡啶类羟肟酸化合物及其制备方法和应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1269800A (zh) * 1997-09-08 2000-10-11 詹森药业有限公司 四氢γ－咔啉类化合物
WO2006072608A2 (en) * 2005-01-03 2006-07-13 Universitá Degli Studi Di Siena Aryl piperazine derivatives for the treatment of neuropsychiatric disorders
WO2014100730A1 (en) * 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof
WO2015110263A1 (en) * 2014-01-21 2015-07-30 Ac Immune Sa Carbazole and carboline compounds for use in the diagnosis, treatment, alleviation or prevention of disorders associated with amyloid or amyolid-like proteins
WO2015200677A2 (en) * 2014-06-25 2015-12-30 Epizyme, Inc. Prmt5 inhibitors and uses thereof
WO2016022605A1 (en) * 2014-08-04 2016-02-11 Epizyme, Inc. Prmt5 inhibitors and uses thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3317524A (en) * 1965-02-04 1967-05-02 American Home Prod Substituted 1, 2, 3, 4-tetrahydro-pyrazino[1, 2-a]indoles
US3687961A (en) * 1971-05-03 1972-08-29 Abbott Lab 8-fluoro-2-{8 3-(4-fluorophenylanilinopropyl{9 -gamma-carboline
US4001263A (en) 1974-04-01 1977-01-04 Pfizer Inc. 5-Aryl-1,2,3,4-tetrahydro-γ-carbolines
DE2854014A1 (de) * 1978-12-14 1980-07-03 Troponwerke Gmbh & Co Kg 7,8,9,10-tetrahydrothieno eckige klammer auf 3,2-e eckige klammer zu pyrido eckige klammer auf 4,3-b eckige klammer zu indole, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
US4719211A (en) 1984-05-01 1988-01-12 American Home Products Corporation 2,3,4,9-tetrahydro-2-heteroarylalkyl-1H-pyrido(3,4-B)indoles having antihypertensive properties
SU1248223A1 (ru) * 1985-01-07 1995-09-20 Научно-Исследовательский Институт По Биологическим Испытаниям Химических Соединений ДИГИДРОХЛОРИД 2-(3-ИЗОПРОПИЛАМИНО-2-ГИДРОКСИПРОПИЛ)-1,2,3,4-ТЕТРАГИДРО- β -КАРБОЛИНА, ОБЛАДАЮЩИЙ АНТИАЛКОГОЛЬНЫМ И ПСИХОТРОПНЫМ ДЕЙСТВИЕМ
US4663456A (en) * 1985-09-16 1987-05-05 American Home Products Corporation 2-(substituted piperazinylalkyl)β-carbolines useful in treatment of psychological disorders
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
BR9707495A (pt) 1996-02-13 1999-07-27 Zeneca Ltd Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente
US6291455B1 (en) 1996-03-05 2001-09-18 Zeneca Limited 4-anilinoquinazoline derivatives
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
UA52681C2 (uk) 1997-04-08 2003-01-15 Янссен Фармацевтика Н.В. Похідні 1,2,3,4-тетрагідро-бензофуро[3,2,-c]піридину, спосіб їх одержання та фармацевтична композиція на їх основі
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
SK288365B6 (sk) 1999-02-10 2016-07-01 Astrazeneca Ab Medziprodukty pre chinazolínové deriváty ako inhibítory angiogenézy
NZ522074A (en) 2000-05-31 2004-06-25 Astrazeneca Ab Indole derivatives with vascular damaging activity
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
IL153484A0 (en) 2000-07-07 2003-07-06 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors
CN1255392C (zh) 2000-07-07 2006-05-10 安吉奥金尼药品有限公司 作为血管生成抑制剂的秋水仙醇衍生物
AUPR201600A0 (en) 2000-12-11 2001-01-11 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivative
WO2007079239A2 (en) 2005-12-30 2007-07-12 Acadia Pharmaceuticals Inc. Bicyclic nitrogen compounds as modulators of ghrelin receptor and uses thereof
WO2010080253A1 (en) 2008-12-18 2010-07-15 Merck Patent Gmbh Tricyclic azaindoles
CA2898040A1 (en) 2013-01-14 2014-07-17 Ent Associates Of Los Alamos, Llc Honey nasal rinse
ES2786052T3 (es) 2013-04-23 2020-10-08 Esteve Pharmaceuticals Sa Compuestos de pirazino[1,2-a]indol, su preparación y su uso en medicamentos
EP3013824B8 (en) 2013-06-28 2018-11-21 Alzprotect Carboline compounds usable in the treatment of neurodegenerative diseases
JP2017519737A (ja) 2014-05-26 2017-07-20 バイエル・ファルマ・アクティエンゲゼルシャフト 置換テトラヒドロピリドチエノピリミジン

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1269800A (zh) * 1997-09-08 2000-10-11 詹森药业有限公司 四氢γ－咔啉类化合物
WO2006072608A2 (en) * 2005-01-03 2006-07-13 Universitá Degli Studi Di Siena Aryl piperazine derivatives for the treatment of neuropsychiatric disorders
WO2014100730A1 (en) * 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof
WO2015110263A1 (en) * 2014-01-21 2015-07-30 Ac Immune Sa Carbazole and carboline compounds for use in the diagnosis, treatment, alleviation or prevention of disorders associated with amyloid or amyolid-like proteins
WO2015200677A2 (en) * 2014-06-25 2015-12-30 Epizyme, Inc. Prmt5 inhibitors and uses thereof
WO2016022605A1 (en) * 2014-08-04 2016-02-11 Epizyme, Inc. Prmt5 inhibitors and uses thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Development of Novel 1,2,3,4-Tetrahydroisoquinoline Derivatives and Closely Related Compounds as Potent and Selective Dopamine D3 Receptor Ligands;Ulrich R. Mach等;《ChemBioChem》;20041231;第5卷;第508-518页 *
Discovery of a New Class of Potential Multifunctional Atypical Antipsychotic Agents Targeting Dopamine D3 and Serotonin 5-HT1A and 5-HT2A Receptors: Design, Synthesis, and Effects on Behavior;Stefania Butini等;《J. Med. Chem.》;20091231;第52卷;第151-169页 *
Neuroleptic Activity of Chiral trans -Hexahydro-7-carbolines;Reinhard Sarges等;《Journal of Medicinal Chemistry》;19861231;第29卷(第1期);第8-19页 *
Structure and Property Guided Design in the Identifi cation of PRMT5 Tool Compound EPZ015666;Kenneth W. Duncan等;《ACS Med. Chem. Lett.》;20151202;第7卷;第162-166页 *
吴姗姗.STN.《STN》.2021,第1-3页. *

Also Published As

Publication number Publication date
EP3596073A1 (en) 2020-01-22
CA3056726A1 (en) 2018-09-20
CN110621675A (zh) 2019-12-27
KR102604942B1 (ko) 2023-11-21
WO2018167276A1 (en) 2018-09-20
JP2020510092A (ja) 2020-04-02
GB201704325D0 (en) 2017-05-03
US20200325132A1 (en) 2020-10-15
EP3596073B1 (en) 2022-05-11
US11274098B2 (en) 2022-03-15
KR20190129071A (ko) 2019-11-19
ES2925115T3 (es) 2022-10-13
JP7308765B2 (ja) 2023-07-14

Similar Documents

Publication Publication Date Title
CN110621675B (zh) 用于治疗增殖性疾病的三环化合物
CN110650950B (zh) 用于治疗或预防prmt5介导的疾病的化合物
CN112094269B (zh) 一类饱和六元环并杂环类化合物、制备方法和用途
ES2975661T3 (es) Inhibidores de BCL6 derivados de la 2-quinolona
US9371319B2 (en) Pyrrolopyridineamino derivatives as MPS1 inhibitors
TWI866258B (zh) 用於治療發炎性病症之新穎化合物及其醫藥組合物
AU2017289315B2 (en) Heteroaromatic derivatives as NIK inhibitors
WO2018228275A1 (zh) 作为mnk抑制剂的杂环化合物
CN106459035B (zh) N2‑苯基‑吡啶并[3,4‑d]嘧啶‑2,8‑二胺衍生物及其作为mps1抑制剂的用途
AU2008246351A1 (en) Pyrrolopyrimidin-7-one derivatives and their use as pharmaceuticals
WO2021018118A1 (en) Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 1 proteins
BRPI0807868A2 (pt) Composto ou um sal farmaceuticamente aceitável ou n-óxido do mesmo, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável ou n-óxido, método para o tratamento de um ser humano ou animal que sofre um câncer, e, processo para preparar um composto ou um sal farmaceuticamente aceitável ou n-óxido do mesmo
CN121079086A (zh) DNA聚合酶θ抑制剂
ES2877140T3 (es) Derivados de pirimidinona como inhibidores de Cdc7
CN120858100A (zh) 抑制性化合物
ES2845048T3 (es) Preparación y usos de derivados de pirimidinona
CN117480162A (zh) 用于治疗或预防prmt5介导的疾病的化合物
TW201333016A (zh) 雙環雜環衍生物、其製備方法及醫療用途
RU2785126C2 (ru) Новые соединения и их фармацевтические композиции для лечения воспалительных заболеваний
JP2024527623A (ja) 癌の治療のためのｈｐｋ１阻害剤としての置換ピラジン－２－カルボキサミド阻害剤
BR112019019358B1 (pt) Compostos, composição farmacêutica, uso dos referidos compostos, método in vitro para alterar a expressão gênica em uma célula e combinação compreendendo um composto

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant